How About No, Aunt Carol

Declining the plate for the fourth year running while the family quietly tabs over to incognito and types 'tirzepatide vs retatrutide.'

Filed under Tirzepatide ·Cagrilintide ·Survodutide · #glp-1 ·#holiday-cope ·#stack-life

Active Compounds

Tirzepatide · Dual GIP/GLP-1 Receptor Agonist

A dual GIP/GLP-1 receptor agonist FDA-approved for diabetes and weight management, producing the largest weight loss seen in clinical trials.

Cagrilintide · Amylin Analogue

A long-acting amylin analogue being developed in combination with semaglutide (CagriSema) for enhanced weight loss.

Survodutide · Dual Glucagon/GLP-1 Receptor Agonist

An investigational dual glucagon/GLP-1 receptor agonist from Boehringer Ingelheim and Zealand Pharma. Phase 3 SYNCHRONIZE-1 (April 28, 2026 topline) achieved 16.6% mean weight loss at 76 weeks — the first positive Phase 3 readout in the SYNCHRONIZE obesity program. FDA Fast Track (2021) and Breakthrough Therapy (2024) designations for MASH; full SYNCHRONIZE-1 data at ADA June 2026.

RX: Tirzepatide · Cagrilintide · Survodutide
Dosage: one (1) refused plate
Half-life: until the Christmas invite
Source: manual
Tags: glp-1 , holiday-cope , stack-life
Stamped: 2026-05-26 · Cycle 021
Lot #: LOT-20260526T16:23:17.565Z